Copyright: ©Author(s) 2026.
World J Virol. Mar 25, 2026; 15(1): 116055
Published online Mar 25, 2026. doi: 10.5501/wjv.v15.i1.116055
Published online Mar 25, 2026. doi: 10.5501/wjv.v15.i1.116055
Figure 1 This timeline illustrates over 25 years of human immunodeficiency virus vaccine development efforts.
Early protein vaccines (VAX004, VAX003) failed. RV144 showed modest 31% protection-the only success so far. Adenovirus vectors (STEP, Phambili) were stopped early due to safety risk. Recent poxvirus and mosaic Ad269 (Adenovirus serotype 26) human immunodeficiency virus vaccine trials (HVTN 702, Imbokodo, Mosaico) have also failed. Now, researchers focus on bnAbs, mRNA, and nanoparticle vaccines.
- Citation: Varatharajan S, Krishnasai S, Girish C. Human immunodeficiency virus vaccines: Advances, challenges and future perspectives. World J Virol 2026; 15(1): 116055
- URL: https://www.wjgnet.com/2220-3249/full/v15/i1/116055.htm
- DOI: https://dx.doi.org/10.5501/wjv.v15.i1.116055